Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Fascin Controls Metastatic Colonization and Mitochondrial Oxidative Phosphorylation by Remodeling Mitochondrial Actin Filaments.

Lin S, Huang C, Gunda V, Sun J, Chellappan SP, Li Z, Izumi V, Fang B, Koomen J, Singh PK, Hao J, Yang S.

Cell Rep. 2019 Sep 10;28(11):2824-2836.e8. doi: 10.1016/j.celrep.2019.08.011.

2.

Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer.

Bryant KL, Stalnecker CA, Zeitouni D, Klomp JE, Peng S, Tikunov AP, Gunda V, Pierobon M, Waters AM, George SD, Tomar G, Papke B, Hobbs GA, Yan L, Hayes TK, Diehl JN, Goode GD, Chaika NV, Wang Y, Zhang GF, Witkiewicz AK, Knudsen ES, Petricoin EF 3rd, Singh PK, Macdonald JM, Tran NL, Lyssiotis CA, Ying H, Kimmelman AC, Cox AD, Der CJ.

Nat Med. 2019 Apr;25(4):628-640. doi: 10.1038/s41591-019-0368-8. Epub 2019 Mar 4.

3.

Mitochondrial superoxide disrupts the metabolic and epigenetic landscape of CD4+ and CD8+ T-lymphocytes.

Moshfegh CM, Collins CW, Gunda V, Vasanthakumar A, Cao JZ, Singh PK, Godley LA, Case AJ.

Redox Biol. 2019 Feb 21:101141. doi: 10.1016/j.redox.2019.101141. [Epub ahead of print]

4.

Anti-PD-1/PD-L1 therapy augments lenvatinib's efficacy by favorably altering the immune microenvironment of murine anaplastic thyroid cancer.

Gunda V, Gigliotti B, Ashry T, Ndishabandi D, McCarthy M, Zhou Z, Amin S, Lee KE, Stork T, Wirth L, Freeman GJ, Alessandrini A, Parangi S.

Int J Cancer. 2019 May 1;144(9):2266-2278. doi: 10.1002/ijc.32041. Epub 2019 Jan 24.

PMID:
30515783
5.

Lysyl Oxidase Is a Key Player in BRAF/MAPK Pathway-Driven Thyroid Cancer Aggressiveness.

Boufraqech M, Patel D, Nilubol N, Powers A, King T, Shell J, Lack J, Zhang L, Gara SK, Gunda V, Klubo-Gwiezdzinska J, Kumar S, Fagin J, Knauf J, Parangi S, Venzon D, Quezado M, Kebebew E.

Thyroid. 2019 Jan;29(1):79-92. doi: 10.1089/thy.2018.0424. Epub 2018 Dec 28.

PMID:
30398411
6.

Evaluating the Metabolic Alterations in Pancreatic Cancer.

Dasgupta A, Shukla SK, Gunda V, King RJ, Singh PK.

Methods Mol Biol. 2019;1882:221-228. doi: 10.1007/978-1-4939-8879-2_20.

PMID:
30378058
7.

Combinations of BRAF inhibitor and anti-PD-1/PD-L1 antibody improve survival and tumour immunity in an immunocompetent model of orthotopic murine anaplastic thyroid cancer.

Gunda V, Gigliotti B, Ndishabandi D, Ashry T, McCarthy M, Zhou Z, Amin S, Freeman GJ, Alessandrini A, Parangi S.

Br J Cancer. 2018 Nov;119(10):1223-1232. doi: 10.1038/s41416-018-0296-2. Epub 2018 Oct 17.

PMID:
30327563
8.

RNA-Binding Protein HuR Regulates Both Mutant and Wild-Type IDH1 in IDH1-Mutated Cancer.

Zarei M, Lal S, Vaziri-Gohar A, O'Hayer K, Gunda V, Singh PK, Brody JR, Winter JM.

Mol Cancer Res. 2019 Feb;17(2):508-520. doi: 10.1158/1541-7786.MCR-18-0557. Epub 2018 Sep 28.

PMID:
30266754
9.

Circulating BRAFV600E Levels Correlate with Treatment in Patients with Thyroid Carcinoma.

Lubitz CC, Zhan T, Gunda V, Amin S, Gigliotti BJ, Fingeret AL, Holm TM, Wachtel H, Sadow PM, Wirth LJ, Sullivan RJ, Panka DJ, Parangi S.

Thyroid. 2018 Mar;28(3):328-339. doi: 10.1089/thy.2017.0322. Epub 2018 Feb 27.

10.

PD-L1 and IDO1 Are Expressed in Poorly Differentiated Thyroid Carcinoma.

Rosenbaum MW, Gigliotti BJ, Pai SI, Parangi S, Wachtel H, Mino-Kenudson M, Gunda V, Faquin WC.

Endocr Pathol. 2018 Mar;29(1):59-67. doi: 10.1007/s12022-018-9514-y.

11.

Hypoxia-Induced Metabolomic Alterations in Pancreatic Cancer Cells.

Gunda V, Kumar S, Dasgupta A, Singh PK.

Methods Mol Biol. 2018;1742:95-105. doi: 10.1007/978-1-4939-7665-2_9.

PMID:
29330793
12.

CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation.

Deng J, Wang ES, Jenkins RW, Li S, Dries R, Yates K, Chhabra S, Huang W, Liu H, Aref AR, Ivanova E, Paweletz CP, Bowden M, Zhou CW, Herter-Sprie GS, Sorrentino JA, Bisi JE, Lizotte PH, Merlino AA, Quinn MM, Bufe LE, Yang A, Zhang Y, Zhang H, Gao P, Chen T, Cavanaugh ME, Rode AJ, Haines E, Roberts PJ, Strum JC, Richards WG, Lorch JH, Parangi S, Gunda V, Boland GM, Bueno R, Palakurthi S, Freeman GJ, Ritz J, Haining WN, Sharpless NE, Arthanari H, Shapiro GI, Barbie DA, Gray NS, Wong KK.

Cancer Discov. 2018 Feb;8(2):216-233. doi: 10.1158/2159-8290.CD-17-0915. Epub 2017 Nov 3.

13.

Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids.

Jenkins RW, Aref AR, Lizotte PH, Ivanova E, Stinson S, Zhou CW, Bowden M, Deng J, Liu H, Miao D, He MX, Walker W, Zhang G, Tian T, Cheng C, Wei Z, Palakurthi S, Bittinger M, Vitzthum H, Kim JW, Merlino A, Quinn M, Venkataramani C, Kaplan JA, Portell A, Gokhale PC, Phillips B, Smart A, Rotem A, Jones RE, Keogh L, Anguiano M, Stapleton L, Jia Z, Barzily-Rokni M, Cañadas I, Thai TC, Hammond MR, Vlahos R, Wang ES, Zhang H, Li S, Hanna GJ, Huang W, Hoang MP, Piris A, Eliane JP, Stemmer-Rachamimov AO, Cameron L, Su MJ, Shah P, Izar B, Thakuria M, LeBoeuf NR, Rabinowits G, Gunda V, Parangi S, Cleary JM, Miller BC, Kitajima S, Thummalapalli R, Miao B, Barbie TU, Sivathanu V, Wong J, Richards WG, Bueno R, Yoon CH, Miret J, Herlyn M, Garraway LA, Van Allen EM, Freeman GJ, Kirschmeier PT, Lorch JH, Ott PA, Hodi FS, Flaherty KT, Kamm RD, Boland GM, Wong KK, Dornan D, Paweletz CP, Barbie DA.

Cancer Discov. 2018 Feb;8(2):196-215. doi: 10.1158/2159-8290.CD-17-0833. Epub 2017 Nov 3.

14.

MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer.

Shukla SK, Purohit V, Mehla K, Gunda V, Chaika NV, Vernucci E, King RJ, Abrego J, Goode GD, Dasgupta A, Illies AL, Gebregiworgis T, Dai B, Augustine JJ, Murthy D, Attri KS, Mashadova O, Grandgenett PM, Powers R, Ly QP, Lazenby AJ, Grem JL, Yu F, Matés JM, Asara JM, Kim JW, Hankins JH, Weekes C, Hollingsworth MA, Serkova NJ, Sasson AR, Fleming JB, Oliveto JM, Lyssiotis CA, Cantley LC, Berim L, Singh PK.

Cancer Cell. 2017 Sep 11;32(3):392. doi: 10.1016/j.ccell.2017.08.008. No abstract available.

15.

De Novo Lipid Synthesis Facilitates Gemcitabine Resistance through Endoplasmic Reticulum Stress in Pancreatic Cancer.

Tadros S, Shukla SK, King RJ, Gunda V, Vernucci E, Abrego J, Chaika NV, Yu F, Lazenby AJ, Berim L, Grem J, Sasson AR, Singh PK.

Cancer Res. 2017 Oct 15;77(20):5503-5517. doi: 10.1158/0008-5472.CAN-16-3062. Epub 2017 Aug 15.

16.

Glucose Limitation Alters Glutamine Metabolism in MUC1-Overexpressing Pancreatic Cancer Cells.

Gebregiworgis T, Purohit V, Shukla SK, Tadros S, Chaika NV, Abrego J, Mulder SE, Gunda V, Singh PK, Powers R.

J Proteome Res. 2017 Oct 6;16(10):3536-3546. doi: 10.1021/acs.jproteome.7b00246. Epub 2017 Aug 30.

17.

MUC1-Mediated Metabolic Alterations Regulate Response to Radiotherapy in Pancreatic Cancer.

Gunda V, Souchek J, Abrego J, Shukla SK, Goode GD, Vernucci E, Dasgupta A, Chaika NV, King RJ, Li S, Wang S, Yu F, Bessho T, Lin C, Singh PK.

Clin Cancer Res. 2017 Oct 1;23(19):5881-5891. doi: 10.1158/1078-0432.CCR-17-1151. Epub 2017 Jul 18.

18.

MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer.

Shukla SK, Purohit V, Mehla K, Gunda V, Chaika NV, Vernucci E, King RJ, Abrego J, Goode GD, Dasgupta A, Illies AL, Gebregiworgis T, Dai B, Augustine JJ, Murthy D, Attri KS, Mashadova O, Grandgenett PM, Powers R, Ly QP, Lazenby AJ, Grem JL, Yu F, Matés JM, Asara JM, Kim JW, Hankins JH, Weekes C, Hollingsworth MA, Serkova NJ, Sasson AR, Fleming JB, Oliveto JM, Lyssiotis CA, Cantley LC, Berim L, Singh PK.

Cancer Cell. 2017 Jul 10;32(1):71-87.e7. doi: 10.1016/j.ccell.2017.06.004. Erratum in: Cancer Cell. 2017 Sep 11;32(3):392.

19.

Correction: MUC1 facilitates metabolomic reprogramming in triple-negative breast cancer.

Goode G, Gunda V, Chaika NV, Purohit V, Yu F, Singh PK.

PLoS One. 2017 Jun 1;12(6):e0179098. doi: 10.1371/journal.pone.0179098. eCollection 2017.

20.

MUC1 facilitates metabolomic reprogramming in triple-negative breast cancer.

Goode G, Gunda V, Chaika NV, Purohit V, Yu F, Singh PK.

PLoS One. 2017 May 2;12(5):e0176820. doi: 10.1371/journal.pone.0176820. eCollection 2017. Erratum in: PLoS One. 2017 Jun 1;12 (6):e0179098.

21.

GOT1-mediated anaplerotic glutamine metabolism regulates chronic acidosis stress in pancreatic cancer cells.

Abrego J, Gunda V, Vernucci E, Shukla SK, King RJ, Dasgupta A, Goode G, Murthy D, Yu F, Singh PK.

Cancer Lett. 2017 Aug 1;400:37-46. doi: 10.1016/j.canlet.2017.04.029. Epub 2017 Apr 26.

22.

Inhibition of MAPKinase pathway sensitizes thyroid cancer cells to ABT-737 induced apoptosis.

Gunda V, Sarosiek KA, Brauner E, Kim YS, Amin S, Zhou Z, Letai A, Parangi S.

Cancer Lett. 2017 Jun 1;395:1-10. doi: 10.1016/j.canlet.2017.02.028. Epub 2017 Mar 1.

PMID:
28259821
23.

Theranostic near-infrared fluorescent nanoplatform for imaging and systemic siRNA delivery to metastatic anaplastic thyroid cancer.

Liu Y, Gunda V, Zhu X, Xu X, Wu J, Askhatova D, Farokhzad OC, Parangi S, Shi J.

Proc Natl Acad Sci U S A. 2016 Jul 12;113(28):7750-5. doi: 10.1073/pnas.1605841113. Epub 2016 Jun 24.

24.
25.

Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer.

Brauner E, Gunda V, Vanden Borre P, Zurakowski D, Kim YS, Dennett KV, Amin S, Freeman GJ, Parangi S.

Oncotarget. 2016 Mar 29;7(13):17194-211. doi: 10.18632/oncotarget.7839.

26.

Detection of Circulating BRAF(V600E) in Patients with Papillary Thyroid Carcinoma.

Lubitz CC, Parangi S, Holm TM, Bernasconi MJ, Schalck AP, Suh H, Economopoulos KP, Gunda V, Donovan SE, Sadow PM, Wirth LJ, Sullivan RJ, Panka DJ.

J Mol Diagn. 2016 Jan;18(1):100-8. doi: 10.1016/j.jmoldx.2015.08.003. Epub 2015 Nov 26.

27.

Silibinin-mediated metabolic reprogramming attenuates pancreatic cancer-induced cachexia and tumor growth.

Shukla SK, Dasgupta A, Mehla K, Gunda V, Vernucci E, Souchek J, Goode G, King R, Mishra A, Rai I, Nagarajan S, Chaika NV, Yu F, Singh PK.

Oncotarget. 2015 Dec 1;6(38):41146-61. doi: 10.18632/oncotarget.5843.

28.

Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines.

Varmeh S, Vanden Borre P, Gunda V, Brauner E, Holm T, Wang Y, Sadreyev RI, Parangi S.

Surgery. 2016 Jan;159(1):152-62. doi: 10.1016/j.surg.2015.06.046. Epub 2015 Oct 9.

29.

MUC16-mediated activation of mTOR and c-Myc reprograms pancreatic cancer metabolism.

Shukla SK, Gunda V, Abrego J, Haridas D, Mishra A, Souchek J, Chaika NV, Yu F, Sasson AR, Lazenby AJ, Batra SK, Singh PK.

Oncotarget. 2015 Aug 7;6(22):19118-31.

30.

Metabolic reprogramming induced by ketone bodies diminishes pancreatic cancer cachexia.

Shukla SK, Gebregiworgis T, Purohit V, Chaika NV, Gunda V, Radhakrishnan P, Mehla K, Pipinos II, Powers R, Yu F, Singh PK.

Cancer Metab. 2014 Sep 1;2:18. doi: 10.1186/2049-3002-2-18. eCollection 2014. Erratum in: Cancer Metab. 2014;2:22.

31.
32.

A potential role for immunotherapy in thyroid cancer by enhancing NY-ESO-1 cancer antigen expression.

Gunda V, Frederick DT, Bernasconi MJ, Wargo JA, Parangi S.

Thyroid. 2014 Aug;24(8):1241-50. doi: 10.1089/thy.2013.0680. Epub 2014 Jun 30.

33.

Blocks to thyroid cancer cell apoptosis can be overcome by inhibition of the MAPK and PI3K/AKT pathways.

Gunda V, Bucur O, Varnau J, Vanden Borre P, Bernasconi MJ, Khosravi-Far R, Parangi S.

Cell Death Dis. 2014 Mar 6;5:e1104. doi: 10.1038/cddis.2014.78.

34.

Impacted mandibular third molars and their influence on mandibular angle and condyle fractures--a retrospective study.

Gaddipati R, Ramisetty S, Vura N, Kanduri RR, Gunda VK.

J Craniomaxillofac Surg. 2014 Oct;42(7):1102-5. doi: 10.1016/j.jcms.2014.01.038. Epub 2014 Jan 15.

PMID:
24530072
35.

Extra cellular matrix derived metabolite regulates angiogenesis by FasL mediated apoptosis.

Verma RK, Gunda V, Pawar SC, Sudhakar YA.

PLoS One. 2013 Dec 4;8(12):e80555. doi: 10.1371/journal.pone.0080555. eCollection 2013.

36.

The next generation of orthotopic thyroid cancer models: immunocompetent orthotopic mouse models of BRAF V600E-positive papillary and anaplastic thyroid carcinoma.

Vanden Borre P, McFadden DG, Gunda V, Sadow PM, Varmeh S, Bernasconi M, Jacks T, Parangi S.

Thyroid. 2014 Apr;24(4):705-14. doi: 10.1089/thy.2013.0483. Epub 2014 Jan 24.

37.

Potential role of 5-aza-2'-deoxycytidine induced MAGE-A4 expression in immunotherapy for anaplastic thyroid cancer.

Gunda V, Cogdill AP, Bernasconi MJ, Wargo JA, Parangi S.

Surgery. 2013 Dec;154(6):1456-62; discussion 1462. doi: 10.1016/j.surg.2013.07.009.

38.

Developments in purification methods for obtaining and evaluation of collagen derived endogenous angioinhibitors.

Gunda V, Verma RK, Pawar SC, Sudhakar YA.

Protein Expr Purif. 2014 Feb;94:46-52. doi: 10.1016/j.pep.2013.10.021. Epub 2013 Nov 9. Review.

39.

Inhibition of elastin peptide-mediated angiogenic signaling mechanism(s) in choroidal endothelial cells by the α6(IV)NC1 collagen fragment.

Gunda V, Verma RK, Sudhakar YA.

Invest Ophthalmol Vis Sci. 2013 Dec 17;54(13):7828-35. doi: 10.1167/iovs.12-10870.

40.
41.
42.

Transcription factor Nrf2 regulates SHP and lipogenic gene expression in hepatic lipid metabolism.

Huang J, Tabbi-Anneni I, Gunda V, Wang L.

Am J Physiol Gastrointest Liver Physiol. 2010 Dec;299(6):G1211-21. doi: 10.1152/ajpgi.00322.2010. Epub 2010 Oct 7.

43.

Insights into the binding mode and mechanism of action of some atypical retinoids as ligands of the small heterodimer partner (SHP).

Cellanetti M, Gunda V, Wang L, Macchiarulo A, Pellicciari R.

J Comput Aided Mol Des. 2010 Nov;24(11):943-56. doi: 10.1007/s10822-010-9386-9. Epub 2010 Sep 30.

44.

Overexpression of nuclear receptor SHP in adipose tissues affects diet-induced obesity and adaptive thermogenesis.

Tabbi-Anneni I, Cooksey R, Gunda V, Liu S, Mueller A, Song G, McClain DA, Wang L.

Am J Physiol Endocrinol Metab. 2010 May;298(5):E961-70. doi: 10.1152/ajpendo.00655.2009. Epub 2010 Feb 2.

45.

Chemical examination of the Sponge Phycopsis sp.

Kondempudi CM, Singanaboina R, Manchala N, Gunda VG, Janapala VR, Yenamandra V.

Chem Pharm Bull (Tokyo). 2009 Sep;57(9):990-2.

46.

Effects of dissolved oxygen levels on survival and growth in vitro of Haliclona pigmentifera (Demospongiae).

Gunda VG, Janapala VR.

Cell Tissue Res. 2009 Sep;337(3):527-35. doi: 10.1007/s00441-009-0843-5. Epub 2009 Aug 4.

PMID:
19653007
47.

Self-amputation of the ear: three men amputate four ears within five months.

Alroe CJ, Gunda V.

Aust N Z J Psychiatry. 1995 Sep;29(3):508-12.

PMID:
8573057

Supplemental Content

Support Center